Adicet Bio Inc (ACET)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.99-6.78%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Adicet Bio Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.529
Annual ending 2026-12-31
Revenue	—	2.86M
EPS	—	-6.359
Annual ending 2027-12-31
Revenue	—	28.52M
EPS	—	-4.04

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain capital to fund operations into second half of 2027	The company plans to keep cash to fund operations into late 2027.	Intact	cash runs out before second half of 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 quarters (2026-Q1 and 2026-Q2) that cash and equivalents will fund operations into second half of 2027. Cash decreased from $137.6M in 2026-Q1 to $118.2M in 2026-Q2. Despite the decline, management maintains sufficient runway. The trajectory shows expected cash burn but aligns with stated funding horizon. Delivery assessment Oct 24, 2026
Advance clinical development of allogeneic gamma delta T cell therapies	Adicet Bio focuses on developing new cancer cell therapies.	Improving	clinical development stalls or regresses in 2026	Qualitative: FDA clearance for ADI-212 Phase 1 (Aug 2026) and Prula-cel data (Sep 2026) confirm sustained advancement. FDA cleared ADI-212 Phase 1 trial in August 2026; Prula-cel Phase 1 preliminary data released in September 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating expenses to support clinical development	A supporting condition in Adicet Bio Inc's published investment case. The stated target is reduce operating loss to about -$21.57M by 2026-Q1.	Intact	operating loss worsens beyond -$21.57M in 2026-Q1	Operating income: $-22.301M FY2026-Q2; GAAP. Published target: reduce operating loss to about -$21.57M by 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 5, 2026-22,301,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: dbb5a79e-d98e-43d0-ab94-f3fe31eb1129. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 quarters (2026-Q1 and 2026-Q2) with R&D expenses around $17.5M-$18.5M and G&A expenses around $3.9M-$4.1M, reflecting controlled spending to support clinical development. Operating expenses decreased from $21.6M in 2026-Q1 to $22.3M in 2026-Q2, showing stable cost management. The trajectory is consistent with management's cost discipline priority. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$-4.19 → Unavailable · observed estimates

FY2027 revenue$0.03B

$0.03B → $0.03B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.19	$34,226,400	5 / 5
2026-07-25	Unavailable	Unavailable	4 / 4
2026-07-26	Unavailable	Unavailable	4 / 4
2026-07-27	Unavailable	Unavailable	4 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	Unavailable	4 / 4
2026-07-30	Unavailable	Unavailable	4 / 4
2026-07-31	Unavailable	Unavailable	3 / 4
2026-08-01	Unavailable	Unavailable	4 / 4
2026-08-02	Unavailable	Unavailable	4 / 4
2026-08-03	Unavailable	Unavailable	4 / 4
2026-08-04	Unavailable	Unavailable	4 / 4
2026-08-05	Unavailable	Unavailable	4 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	4 / 4
2026-08-08	Unavailable	Unavailable	3 / 1
2026-08-09	Unavailable	Unavailable	3 / 1
2026-08-10	Unavailable	Unavailable	3 / 1
2026-08-11	Unavailable	Unavailable	4 / 4
2026-08-12	Unavailable	Unavailable	4 / 4
2026-08-13	Unavailable	Unavailable	4 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	$28,522,017	4 / 5
2026-08-22	Unavailable	$28,522,017	4 / 5
2026-08-23	Unavailable	$28,522,017	4 / 5
2026-08-24	Unavailable	$28,522,017	4 / 5
2026-08-25	Unavailable	$28,522,017	4 / 5
2026-08-26	Unavailable	$28,522,017	4 / 5
2026-08-27	Unavailable	$28,522,017	4 / 5
2026-08-28	Unavailable	$28,522,017	4 / 5
2026-08-29	Unavailable	$28,522,000	4 / 5
2026-08-30	Unavailable	$28,522,000	4 / 5
2026-08-31	Unavailable	$28,522,000	4 / 5
2026-09-01	Unavailable	$28,522,000	4 / 5
2026-09-02	Unavailable	$28,522,000	4 / 5
2026-09-03	Unavailable	$28,516,667	4 / 6
2026-09-04	Unavailable	$28,516,667	4 / 6
2026-09-05	Unavailable	$28,516,667	4 / 6
2026-09-06	Unavailable	$28,516,667	4 / 6
2026-09-07	Unavailable	$28,516,667	4 / 6
2026-09-08	Unavailable	$28,516,667	4 / 6
2026-09-09	Unavailable	$28,516,667	4 / 6
2026-09-10	Unavailable	$28,516,667	4 / 6
2026-09-11	Unavailable	$28,516,667	4 / 6
2026-09-12	Unavailable	$28,522,000	4 / 6
2026-09-13	Unavailable	$28,522,000	4 / 6
2026-09-14	Unavailable	$28,522,000	4 / 6
2026-09-15	Unavailable	$28,522,000	4 / 6
2026-09-16	Unavailable	$28,522,000	4 / 6
2026-09-17	Unavailable	$28,522,000	4 / 6
2026-09-18	Unavailable	$28,522,000	4 / 6
2026-09-19	Unavailable	$28,516,667	4 / 6
2026-09-20	Unavailable	$28,516,667	4 / 6
2026-09-21	Unavailable	$28,516,667	4 / 6
2026-09-22	Unavailable	$28,516,667	4 / 6
2026-09-23	Unavailable	$28,516,667	4 / 6
2026-09-24	Unavailable	$28,516,667	4 / 6
2026-09-25	Unavailable	$28,516,667	4 / 6
2026-09-26	Unavailable	$28,516,667	4 / 6
2026-09-27	Unavailable	$28,516,667	4 / 6
2026-09-28	Unavailable	$28,516,667	4 / 6
2026-09-29	Unavailable	$28,516,667	4 / 6
2026-09-30	Unavailable	$28,516,667	4 / 6
2026-10-01	Unavailable	$28,516,667	4 / 6
2026-10-02	Unavailable	$28,516,667	4 / 6
2026-10-03	Unavailable	$28,516,667	4 / 6
2026-10-04	Unavailable	$28,516,667	4 / 6
2026-10-05	Unavailable	$28,516,667	4 / 6
2026-10-06	Unavailable	$28,516,667	4 / 6
2026-10-07	Unavailable	$28,516,667	4 / 6
2026-10-08	Unavailable	$28,516,667	4 / 6
2026-10-09	Unavailable	$28,516,667	4 / 6
2026-10-10	Unavailable	$28,516,667	4 / 6
2026-10-11	Unavailable	$28,516,667	4 / 6
2026-10-12	Unavailable	$28,516,667	4 / 6
2026-10-13	Unavailable	$28,516,667	4 / 6
2026-10-14	Unavailable	$28,516,667	4 / 6
2026-10-15	Unavailable	$28,516,667	4 / 6
2026-10-16	Unavailable	$28,516,667	4 / 6
2026-10-17	Unavailable	$28,516,667	4 / 6
2026-10-18	Unavailable	$28,516,667	4 / 6
2026-10-19	Unavailable	$28,516,667	4 / 6
2026-10-20	Unavailable	$28,516,667	4 / 6
2026-10-21	Unavailable	$28,516,667	4 / 6
2026-10-22	Unavailable	$28,516,667	4 / 6
2026-10-23	Unavailable	$28,516,667	4 / 6
2026-10-24	Unavailable	$28,516,667	4 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	0	0
2026-06-01	6	0	0
2026-07-01	6	0	0
2026-08-01	6	0	0
2026-09-01	6	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain capital to fund operations into second half of 2027Direct metric needs a verified mapping
Manage operating expenses to support clinical developmentOperating income: $-22.301M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-72.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Adicet Bio Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-development business, not an established earnings compounder. The long-term thesis is intact, with clinical milestones progressing on schedule, but losses, high risk, and a short funding horizon keep the evidence mixed.

What's priced into Adicet Bio Inc

The valuation evidence describes ACET as cheap versus peers, with medium confidence, while the business remains loss-making. No valuation fragility flags are present, but the evidence does not specify what clinical success or failure the market assumes.

What the fundamentals likely do

Near term, the company is expected to remain loss-making as it funds research and development; cash declined from $137.6 million in the first quarter of 2026 to $118.2 million in the second quarter. Management says cash can fund operations into the second half of 2027, while clinical milestones for prula-cel and ADI-212 remain on their stated schedules. Earnings-miss risk is elevated, and a guidance cut, weaker jobs data, or the September litigation filing could weigh on the business outlook; two recent earnings beats offer some support.

What Adicet Bio Inc hinges on

Over the next year, the thesis hinges on prula-cel clinical updates and the planned pivotal-trial startup, plus the regulatory filing and Phase 1 start for ADI-212. Timely progress would support the development case, while delays or weaker guidance would add concern as cash is used. Broader sector support may help sentiment, but weakening employment could increase pressure on cyclical healthcare names.